| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
glucose tolerance
with high-fat high-sucrose diet |
Area under curve. | DO population | both | 4-26wks | 2018 |
|
|
monitoring system
with high-fat diet |
Oxygen consumption and respiratory exchange ratio (RER); activity. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
glucose tolerance
with high-fat diet |
Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
body temperature
with high-fat diet |
In cold room: 0, 1, 2, 3, 4, 5, 6 h. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
|
monitoring system
with high-fat diet |
Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
|
intake monitoring | Water intake. Daily. | inbred (13) | m | 7-8wks | 2011 |
|
|
alcohol quantification
with ethanol |
Blood alcohol concentrations after ethanol injection over time, acute functional ethanol tolerance. | ILSXISS w/par (74) | both | 8-14wks | 2007 |
|
|
monitoring system | O2 consumption, CO2 production, RER, heat expenditure, activity. | both | 8-20wks | 2021 | |
|
|
intake monitoring | Food intake; energy intake; protein, carbohydrate, fat intake. | both | 8-20wks | 2021 | |
|
|
metabolite quantification | Vitamin D concentration (serum). | inbred (18) | m | 11wks | 2011 |
|
|
intake monitoring
with sucrose |
Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. | inbred (12) | m | 13-17wks | 2006 |
|
|
study archive
with ethanol |
Sensitivity to ethanol. Baseline and ethanol. | QTL population | both | 9-34wks | 2012 |
|
|
glucose tolerance
with high-fat diet |
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
|
drug and metabolite quantification
with diazepam |
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. | inbred (15) | both | 6-7wks | 1998 |
|
|
body temperature
with diazepam |
Baseline vs. 30 min after diazepam injection (several doses). | inbred (15) | both | 6-7wks | 1998 |
|
|
alcohol quantification
with ethanol |
Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. | inbred (21) | both | 9-17wks | 2003 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
glucose tolerance | 0 to 180 min after 20% glucose i.p. 16h fast. | inbred (4) | both | 12, 24, 52 wks | 2008 |
|
|
body temperature | Hourly readings in cold room. 6h test. | inbred (4) | both | 12wks | 2008 |
|
|
intake monitoring | Food intake, water intake at 6mo. Light phase, dark phase, total. | inbred (14) | both | 25wks | 2009 |
|
|
monitoring system | Locomotor activity and energy metabolism. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
intake monitoring | Food, water intake. 21h test. | inbred w/CC8 (8) | both | 12-13wks | 2020 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | inbred w/CC8 (6) | both | 13-14wks | 2020 |
|
|
drug and metabolite quantification
with lithium |
Lithium concentration in brain tissue and blood serum after lithium (several doses). | inbred (11) | m | 7-8wks | 2011 |
|
|
drug and metabolite quantification
with nicotine |
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. | inbred (8) | m | 8-12wks | 2011 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 8-18wks | 2021 |
|
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 66-81wks | 2021 |
|
|
protein activity assessment
with exercise |
Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. | inbred (6) | m | 11-14wks | 2012 |
|
|
intake monitoring
with exercise |
Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
monitoring system
with exercise |
Respiratory exchange ratio. Baseline (before access to running wheel). | CC pre w/par (184) | m | 10-12wks | 2011 |
|
|
monitoring system
with exercise |
Locomotor activity, respiratory activity, body heat production, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
intake monitoring
with exercise |
Food and water intake, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. | CC (4) | both | 8-10wks | 2018 |
|
|
protein activity assessment | Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus | inbred (20) | m | 8-12wks | 2021 |
|
|
metabolic panel | Male reproductive sperm lactate production. | inbred (8) | m | 10-66wks | 2015 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. | inbred (17) | m | 7wks | 2010 |
|
|
alcohol quantification
with high-fat diet and ethanol |
Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. | inbred (14) | m | 8-14wks | 2011 |
|
|
drug and metabolite quantification
with trichloroethylene |
Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. | inbred (7) | m | 6-7wks | 2014 |
|
|
glucose tolerance | 0 to 120 min after 10% glucose i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
insulin tolerance | 0 to 120 min after insulin i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
|
glucose tolerance
with high-fat diet |
Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
|
monitoring system | Locomotor activity and energy metabolism. 24h test. | inbred (16) | both | 7-9wks | 2001 |
|
|
intake monitoring | Food, caloric, and water intake. Daily. | inbred (16) | both | 7-9wks | 2001 |
|
|
drug and metabolite quantification
with acetaminophen |
Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). | inbred (5) | m | 6-8wks | 2005 |
|
|
intake monitoring | Food intake, water intake. Daily. | inbred (28) | m | 4-12wks | 2001 |
|
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
|
body weight | Body weight | CC RIX (73) | both | 7-13wks | 2020 |
|
|
inclined screen test | Latency to move all four paws. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
open field test | Locomotor activity, anxiety, stereotypy. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
behavior observation | Vacuous chewing, tongue protrusion, jaw tremor. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
drug and metabolite quantification | Plasma haloperidol concentration. | CC RIX (73) | both | 7-13wks | 2020 |
|
|
intake monitoring
with arsenic |
Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure | DO population | m | 4-34 wks | 2022 |
|
|
metabolite quantification
with arsenic |
iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) | DO population | m | 4-34 wks | 2022 |
|
|
intake monitoring | Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |
|
|
monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |